While one side highlights how plan sponsors can contribute to biosimilar sustainability, the other touts the benefits to patients and the health-care system. Durhane Wong-Rieger, president and chief executive officer, Institute for Optimizing Health Outcomes The Institute for Optimizing Health Outcomes recently published a scorecard rating the biosimilar policy frameworks of European countries across seven […]
Two experts weigh in on the merits and drawbacks of taking the traditional annuities route versus opting for the newer do-it-yourself option. Marco Dickner, retirement risk management leader for Willis Towers Watson in Canada Although annuity purchases have become an important pension risk management option over the last decade, a countertrend is emerging for plan […]
On Dec. 9, the 2020 Face to Face Drug Plan Management Forum featured sessions on prior authorization, Canadian drug policy issues and impacts, plan design considerations related to chronic disease and pharmacy benefits management. Here’s what you missed! Biosimilars, pharmacogenetics shaping the future of pharmacy benefits management Plan sponsors with growing concerns about benefits plan […]